The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis.
Osteoporosis can affect almost everyone in the population, and although clinical outcome of fracture is manifested in late life, the disease process begins in the early postmenopausal years in women. The pharmacologic agents currently available for osteoporosis prevention and treatment act by inhibiting bone resorption, and include estrogen or hormone replacement therapy (estrogen with progestin), bisphosphonates, salmon calcitonin nasal spray, and selective estrogen receptor modulators (SERMs). Raloxifene is a benzothiophene SERM that has estrogen against effects in bone and on serum lipid metabolism and estrogen antagonist effects on breast and uterine tissue. This article summarizes the effects of these antiresorptive agents, as measured by changes in bone mineral density, biochemical markers of bone turnover, and incident fractures in postmenopausal osteoporosis.
Lufkin
E G
EG
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA.
Wong
M
M
Deal
C
C
D000368:Aged; D000818:Animals; D015519:Bone Density / Q000187:drug effects; D004965:Estrogen Antagonists / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D005260:Female; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000517:prevention & control*; D020849:Raloxifene Hydrochloride / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D011960:Receptors, Estrogen / Q000819:agonists / Q000037:antagonists & inhibitors; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*
D004965:Estrogen Antagonists; D011960:Receptors, Estrogen; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride